ClinicalTrials.gg
CompletedNCT02120950PLANETUpdated Dec 2, 2020Results posted

Aflibercept in Polypoidal Choroidal Vasculopathy

A Phase 4 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) and Visudyne in Neovascular Macular Degeneration, sponsored by Bayer. Completed at 62 sites in 8 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-12-02.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
12th of 66
333 · median 55
Started
2014
with 11 others
Phase 4
27 of 66
none open now
Registered
20th of 66
by date
Lead sponsor
8 of 66
Bayer

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 12th largest by enrollment, is one of 12 that started in 2014, is one of 27 in phase 4, and was the 20th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration

03

Conditions studied

  • Neovascular Macular Degeneration

Keywords

  • PCV
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Men and women ≥50 years of age
  • Diagnosis of symptomatic macular Polypoidal Choroidal Vasculopathy (PCV) in the study eye established by Indocyanine Green Angiography(ICGA) at the study center
  • Greatest linear dimension of the lesion of \< 5400 mm (approximately, 9 Macular Photocoagulation Study disk areas), assessed by ICGA.
  • An Early treatment diabetic retinopathy study (ETDRS) BCVA of 73 to 24 letters in the study eye.

Exclusion criteria

Exclusion Criteria:

  • Prior use of intravitreal or sub-tenon in the study eye within 3 months prior to study entry
  • Any prior use of intraocular anti Vascular Endothelial Growth Factor (anti-VEGF)agents in the study eye, or systemic use of anti VEGF products within 3 months prior to study entry
  • Prior macular laser treatment in the study eye including Photodynamic Therapy (PDT)
  • History of allergy to fluorescein used in fluorescein angiography, iodine and/or indocyanine green.
  • History of allergy to aflibercept, verteporfin, or their .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
333 participants (actual)

Study arms

  • Experimental
    Aflibercept + Sham PDT

    Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    Aflibercept + Active PDT

    Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) · Other: Visudyne

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

    Time frame: From Baseline to Week 52

Secondary outcomes

  1. Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52

    Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

    Time frame: At Week 52

Other outcomes

  1. Percentage of Subjects Who Never Need Rescue Therapy in the First Year

    Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.

    Time frame: Baseline to Week 52

  2. Number of PDT Treatments in the Study Eye Before Week 52

    Time frame: Baseline to Week 52

  3. Number of Aflibercept Treatments in the Study Eye (After Randomization) Before Week 52

    Time frame: Baseline to Week 52

  4. Time to First Administration of PDT in the Study Eye Before Week 52

    Time frame: Baseline to Week 52

  5. Change of Visual Acuity (Letters) From Baseline Over Time (Week) in the Study Eye

    Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

    Time frame: Baseline to Week 52

  6. Percentage of Subjects Who Gained ≥5, 10, or 15 Letters at Week 52

    Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

    Time frame: Baseline to Week 52

  7. Percentage of Subjects Who Lost ≥5, 10, or 15 Letters at Week 52

    Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

    Time frame: Baseline to Week 52

  8. Percentage of Subjects With Complete Polyp Regression at Week 52

    Complete polyp regression was defined as absent or indeterminate visual polyps on Indocyanine green angiography (ICGA) in the study eye.

    Time frame: Baseline to Week 52

  9. Change of Leakage Area in Fluorescein Angiography (FA) in the Study Eye at Week 52

    Leakage is the release of fluorescein dye from diseased retinal vessels. Leakage area is defined as the area showing presence of fluorescein dye in the late stages of fluorescein angiography.

    Time frame: Baseline to Week 52

  10. Change of Central Subfield Thickness (CST) on Optical Coherence Tomography (OCT) From Baseline to Week 52

    Retinal and lesion characteristics, such as central retinal thickness (CRT), were evaluated by OCT in both eyes at every study visit. CRT was measured using optical coherence tomography to determine the average thickness of the retina in a circle with 1 millimeter of diameter centered on the fovea. This value is reported by some OCT devices as central subfield thickness (CST).

    Time frame: Baseline to Week 52

  11. Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 52

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.

    Time frame: Baseline to Week 52

  12. Percentage of Subjects for Whom Rescue Therapy is Indicated Over the Course Till Week 52

    Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.

    Time frame: Baseline to Week 52

07

Results

Posted Jan 15, 2019

Participant flow

The study was conducted at multiple centers in 8 countries worldwide starting from 29 May 2014 (first subject first visit). Primary completion reached on 12 Aug 2016.

Participant flow — Overall Study
MilestoneAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDTAflibercept (Non-randomized)
Started15716115
Completed1371470
Not completed201415
Withdrew: Adverse event543
Withdrew: Death301
Withdrew: Withdrawal by subject632
Withdrew: Protocol violation117
Withdrew: Other reasons541
Withdrew: Lost to follow-up021

Outcome measures

PrimaryMean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)

Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

Time frame:
From Baseline to Week 52
Reported as:
Mean · Letters correctly read
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)
Letters correctly readAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)10.7 ± 11.310.8 ± 10.7
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · ANCOVA · p = 0.5480 · Mean difference (net): -0.7 · 95% CI -2.9 to 1.6
SecondaryPercentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52

Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

Time frame:
At Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52
Percentage of subjectsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 5297.596.9
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.7402 · Treatment difference in %: 0.6 · 95% CI -3.1 to 4.3
Other pre-specifiedPercentage of Subjects Who Never Need Rescue Therapy in the First Year

Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Never Need Rescue Therapy in the First Year
Percentage of subjectsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Percentage of Subjects Who Never Need Rescue Therapy in the First Year87.985.7
Other pre-specifiedNumber of PDT Treatments in the Study Eye Before Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · PDT administrations
Number of PDT Treatments in the Study Eye Before Week 52
PDT administrationsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Number of PDT Treatments in the Study Eye Before Week 520.2 ± 0.70.2 ± 0.4
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · ANCOVA · p = 0.0682 · Ls mean difference: 0.1 · 95% CI 0.0 to 0.2Point estimate, 95% CI and p-value are based on treatment difference (AFL-sham - AFL-PDT) of the LS mean changes using an ANOVA model with treatment group and ethnicity and qualification for rescue therapy at Week 12 as fixed effects.
Other pre-specifiedNumber of Aflibercept Treatments in the Study Eye (After Randomization) Before Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Aflibercept injections
Number of Aflibercept Treatments in the Study Eye (After Randomization) Before Week 52
Aflibercept injectionsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Number of Aflibercept Treatments in the Study Eye (After Randomization) Before Week 525.2 ± 1.15.1 ± 0.8
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · ANCOVA · p = 0.1640 · Ls mean difference: 0.1 · 95% CI -0.1 to 0.3Point estimate, 95% CI and p-value are based on treatment difference (AFL-sham - AFL-PDT) of the LS mean changes using an ANOVA model with treatment group and ethnicity and qualification for rescue therapy at Week 12 as fixed effects.
Other pre-specifiedTime to First Administration of PDT in the Study Eye Before Week 52
Time frame:
Baseline to Week 52
Reported as:
Mean · Days
Time to First Administration of PDT in the Study Eye Before Week 52
DaysAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Time to First Administration of PDT in the Study Eye Before Week 52131.2 (80 to 278)128.2 (80 to 315)
Other pre-specifiedChange of Visual Acuity (Letters) From Baseline Over Time (Week) in the Study Eye

Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

Time frame:
Baseline to Week 52
Reported as:
Mean · Letters
Change of Visual Acuity (Letters) From Baseline Over Time (Week) in the Study Eye
LettersAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Change of Visual Acuity (Letters) From Baseline Over Time (Week) in the Study Eye10.7 ± 11.310.8 ± 10.7
Other pre-specifiedPercentage of Subjects Who Gained ≥5, 10, or 15 Letters at Week 52

Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Gained ≥5, 10, or 15 Letters at Week 52
Percentage of subjectsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Gained ≥ 573.978.9
Gained ≥ 1055.457.1
Gained ≥ 1533.136.6
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.2348 · Treatment difference in %: -5.6 · 95% CI -14.9 to 3.7CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.6877 · Treatment difference in %: -2.2 · 95% CI -13.1 to 8.6CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.4556 · Treatment difference in %: -4.0 · 95% CI -14.5 to 6.5CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
Other pre-specifiedPercentage of Subjects Who Lost ≥5, 10, or 15 Letters at Week 52

Visual function of the study eye and fellow eye was assessed at each study visit according to the standard procedure developed for the ETDRS adapted for Age Related Eye Disease Study (AREDS), using 70 letter charts at a starting distance of 4 meters. Participants were challenged with reading letters on lines of an eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until they reached a row where a minimum of three letters on a line could be read, and were scored by how many letters could be correctly identified.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Lost ≥5, 10, or 15 Letters at Week 52
Percentage of subjectsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Lost ≥ 57.05.6
Lost ≥ 103.83.1
Lost ≥ 152.53.1
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.5372 · Treatment difference in %: 1.7 · 95% CI -3.7 to 7.2CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.7569 · Treatment difference in %: 0.6 · 95% CI -3.4 to 4.7CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.7402 · Treatment difference in %: -0.6 · 95% CI -4.3 to 3.1CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
Other pre-specifiedPercentage of Subjects With Complete Polyp Regression at Week 52

Complete polyp regression was defined as absent or indeterminate visual polyps on Indocyanine green angiography (ICGA) in the study eye.

Time frame:
Baseline to Week 52
Reported as:
Number · Percetage of subjects
Percentage of Subjects With Complete Polyp Regression at Week 52
Percetage of subjectsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Percentage of Subjects With Complete Polyp Regression at Week 5238.944.8
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.3244 · Treatment difference in %: -6.0 · 95% CI -17.8 to 5.9CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12
Other pre-specifiedChange of Leakage Area in Fluorescein Angiography (FA) in the Study Eye at Week 52

Leakage is the release of fluorescein dye from diseased retinal vessels. Leakage area is defined as the area showing presence of fluorescein dye in the late stages of fluorescein angiography.

Time frame:
Baseline to Week 52
Reported as:
Mean · Square millimeter
Change of Leakage Area in Fluorescein Angiography (FA) in the Study Eye at Week 52
Square millimeterAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Change of Leakage Area in Fluorescein Angiography (FA) in the Study Eye at Week 52-1.3 ± 3.6-1.2 ± 3.7
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · ANCOVA · p = 0.7109 · Ls mean difference: -0.1 · 95% CI -0.9 to 0.6Point estimate, 95% CI and p-value are based on difference (AFL-sham - AFL-PDT) of LS mean changes using an ANCOVA model with treatment group and ethnicity and qualification for rescue therapy at Week 12 as fixed effects, baseline value as covariate.
Other pre-specifiedChange of Central Subfield Thickness (CST) on Optical Coherence Tomography (OCT) From Baseline to Week 52

Retinal and lesion characteristics, such as central retinal thickness (CRT), were evaluated by OCT in both eyes at every study visit. CRT was measured using optical coherence tomography to determine the average thickness of the retina in a circle with 1 millimeter of diameter centered on the fovea. This value is reported by some OCT devices as central subfield thickness (CST).

Time frame:
Baseline to Week 52
Reported as:
Mean · Millimeter
Change of Central Subfield Thickness (CST) on Optical Coherence Tomography (OCT) From Baseline to Week 52
MillimeterAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Change of Central Subfield Thickness (CST) on Optical Coherence Tomography (OCT) From Baseline to Week 52-137.7 ± 116.0-143.5 ± 110.5
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · ANCOVA · p = 0.8355 · Ls mean difference: 1.1 · 95% CI -9.2 to 11.3Point estimate, 95% CI and p-value are based on difference (AFL-sham - AFL-PDT) of LS mean changes using an ANCOVA model with treatment group and ethnicity and qualification for rescue therapy at Week 12 as fixed effects, baseline value as covariate.
Other pre-specifiedChange in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 52

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.

Time frame:
Baseline to Week 52
Reported as:
Mean · Scores on a scale
Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 52
Scores on a scaleAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 524.7 ± 10.37.3 ± 12.5
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · ANCOVA · p = 0.5069 · Ls mean difference: -0.7 · 95% CI -2.9 to 1.4Point estimate, 95% CI and p-value are based on difference (AFL-sham - AFL-PDT) of LS mean changes using an ANCOVA model with treatment group and ethnicity and qualification for rescue therapy at Week 12 as fixed effects, baseline value as covariate.
Other pre-specifiedPercentage of Subjects for Whom Rescue Therapy is Indicated Over the Course Till Week 52

Evaluations for qualification for rescue were conducted at each visit from Week 12 to Week 52. Intensified aflibercept treatment plus active or sham PDT treatments were given at any of these visits if treatment criteria were met. Qualification for rescue was based upon insufficient gain of BCVA, leakage, and presence of active polyps.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects for Whom Rescue Therapy is Indicated Over the Course Till Week 52
Percentage of subjectsAflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDT
Percentage of Subjects for Whom Rescue Therapy is Indicated Over the Course Till Week 5212.114.3
Statistical analysis
  • Aflibercept + Sham Photodynamic Therapy (PDT) vs Aflibercept + Active PDT · Cochran-Mantel-Haenszel · p = 0.8423 (The p-value is calculated from the 2-sided Cochran-Mantel-Haenszel test adjusted by ethnicity and qualification for rescue therapy at Week 12.) · Difference %: -0.6 · 95% CI -6.3 to 5.1CI is based on the treatment difference in % (AFL-sham - AFL-PDT) using the Mantel-Haenszel weighting scheme adjusted by ethnicity and qualification for rescue therapy at Week 12.

Adverse events

Collected over From start of study treatment up to 30 days after the last treatment. Approximately 100 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept + Sham PDT3/157 (1.9%)27/157 (17.2%)59/157 (37.6%)
Aflibercept + Active PDT0/161 (0%)25/161 (15.5%)49/161 (30.4%)
Aflibercept (Non-randomized)1/15 (6.7%)4/15 (26.7%)3/15 (20%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventAflibercept + Sham PDTAflibercept + Active PDTAflibercept (Non-randomized)
Retinal pigment epithelial tearEye disorders0/1570/1611/15
Sudden cardiac deathGeneral disorders0/1570/1611/15
Acoustic neuromaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1570/1611/15
Senile dementiaNervous system disorders0/1570/1611/15
PneumoniaInfections and infestations0/1573/1610/15
ArrhythmiaCardiac disorders2/1570/1610/15
CataractEye disorders2/1570/1610/15
FallInjury, poisoning and procedural complications2/1570/1610/15
Rib fractureInjury, poisoning and procedural complications2/1570/1610/15
Visual acuity reducedEye disorders0/1572/1610/15
Most frequent other events
Most frequent other events
EventAflibercept + Sham PDTAflibercept + Active PDTAflibercept (Non-randomized)
Viral upper respiratory tract infectionInfections and infestations25/15718/1610/15
HypertensionVascular disorders6/15713/1612/15
Dry eyeEye disorders6/15711/1610/15
Ocular hypertensionEye disorders3/1571/1611/15
Retinal pigment epithelial tearEye disorders4/1570/1611/15
DepressionPsychiatric disorders1/1570/1611/15
Conjunctival haemorrhageEye disorders10/1575/1610/15
Vitreous floatersEye disorders9/1571/1610/15
Visual acuity reducedEye disorders7/1579/1610/15
Intraocular pressure increasedInvestigations6/1579/1610/15

Baseline characteristics

Baseline characteristics is reported in Full analysis set which included all randomized subjects (N=318).

Age, Continuous
Age, Continuous(Years)Aflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDTTotal
Mean70.8 ± 8.470.4 ± 8.070.6 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDTTotal
Female474996
Male110112222
Baseline BCVA score
Baseline BCVA score(Letters)Aflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDTTotal
Mean57.7 ± 11.359.0 ± 11.558.4 ± 11.4
Central Subfield Thickness
Central Subfield Thickness(Micrometer)Aflibercept + Sham Photodynamic Therapy (PDT)Aflibercept + Active PDTTotal
Mean347.8 ± 118.9346.1 ± 117.5346.9 ± 118.0
08

Study locations

62 sites
  • Liverpool, New South Wales 2170, Australia
  • Strathfield, New South Wales 2135, Australia
  • Westmead, New South Wales 2145, Australia
  • East Melbourne, Victoria 3002, Australia
  • Parramatta, 2150, Australia
  • München, 80336, Germany
  • Hong Kong, Hong Kong
  • Kowloon, Hong Kong
  • Budapest, 1082, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Nagoya, Aichi 466-8560, Japan
  • Urayasu, Chiba 279-0021, Japan
  • Ogaki, Gifu 503-0015, Japan
  • Maebashi, Gunma 371-8511, Japan
  • Asahikawa, Hokkaido 078-8510, Japan
  • Sapporo, Hokkaido 060-8604, Japan
  • Amagasaki, Hyogo 660-8550, Japan
  • Kobe, Hyogo 650-0017, Japan
  • Kita, Kagawa 761-0793, Japan
  • Tsu, Mie 514-8507, Japan
  • Kashihara, Nara 634-8522, Japan
  • Hirakata, Osaka 573-1191, Japan
  • Suita, Osaka 565-0871, Japan
  • Otsu, Shiga 520-2192, Japan
  • Hamamatsu, Shizuoka 430-8558, Japan
  • Shimotsuke, Tochigi 329-0498, Japan
  • Bunkyo-ku, Tokyo 113-8655, Japan
  • Chiyoda-ku, Tokyo 101-8309, Japan
  • Meguro-ku, Tokyo 152-8902, Japan
  • Mitaka, Tokyo 181-8611, Japan
  • Shinjuku-ku, Tokyo 160-8582, Japan
  • Shinjuku-ku, Tokyo 162-8666, Japan
  • Akita, 010-8543, Japan
  • Aomori, 030-8553, Japan
  • Chiba, 260-8677, Japan
  • Fukuoka, 812-0011, Japan
  • Fukuoka, 812-8582, Japan
  • Fukushima, 960-1295, Japan
  • Kumamoto, 860-0027, Japan
  • Kyoto, 602-0841, Japan
  • Kyoto, 606-8507, Japan
  • Nagasaki, 852-8511, Japan
  • Okayama, 700-8558, Japan
  • Osaka, 545-8586, Japan
  • Tokushima, 770-8503, Japan
  • Wakayama, 641-8510, Japan
  • Seongnam-si, Gyeonggido 463-707, Korea, Republic of
  • Seoul, 03080, Korea, Republic of
  • Seoul, 05505, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Seoul, 137-701, Korea, Republic of
  • Seoul, 153-950, Korea, Republic of
  • Singapore, 119074, Singapore
  • Singapore, 168751, Singapore
  • Changhua City, Changhua 500, Taiwan
  • Kaohsiung, 81362, Taiwan
  • Taipei City, Taiwan
  • Taipei, 10002, Taiwan
  • Taipei, 10449, Taiwan
  • Taipei, 11217, Taiwan
09

References and documents

Publications

  • Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, Cheung GCM, Zhang Z, Leal S, Ishibashi T; PLANET Investigators. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 Jul 1;136(7):786-793. doi: 10.1001/jamaophthalmol.2018.1804. Erratum In: JAMA Ophthalmol. 2018 Jul 1;136(7):840. doi: 10.1001/jamaophthalmol.2018.2864. PubMed 29801063 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Aug 2016, 26 months.

Results were first posted in Jan 2019, 2 years 5 months after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 26 months is close to that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2014
First posted
Apr 23, 2014
StartActual
May 29, 2014
Primary completionActual
Aug 12, 2016
CompletionActual
Jul 7, 2017
Results first posted
Jan 15, 2019
Last update
Dec 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02120950
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 23, 2014
Start date
May 29, 2014
Primary completion
Aug 12, 2016
Completion
Jul 7, 2017
Results posted
Jan 15, 2019
Last update
Dec 2, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion